{
	"symbol": "CSCI",
	"name": "COSCIENS Biopharma Inc.",
	"price": 4.6,
	"priceChange": -0.1,
	"percentChange": -2.12766,
	"exchangeName": "Toronto Stock Exchange",
	"exShortName": "TSX",
	"exchangeCode": "TSX",
	"marketPlace": null,
	"sector": "Healthcare",
	"industry": "Biotechnology",
	"volume": 100,
	"openPrice": 4.6,
	"dayHigh": 4.6,
	"dayLow": 4.6,
	"MarketCap": 14473864,
	"MarketCapAllClasses": 14475152,
	"peRatio": "",
	"prevClose": 4.7,
	"dividendFrequency": null,
	"dividendYield": null,
	"dividendAmount": null,
	"dividendCurrency": null,
	"beta": 1.768052,
	"eps": null,
	"exDividendDate": "",
	"longDescription": "COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt's Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.",
	"fulldescription": "COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt's Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.",
	"website": "https://www.zentaris.com",
	"email": "IR@aezsinc.com",
	"phoneNumber": "+1 843 900-3223",
	"fullAddress": "c/o Norton Rose Fulbright Canada, LLP,222 Bay Street, Toronto, ON, CA",
	"employees": "21",
	"shareOutStanding": 3146492,
	"totalDebtToEquity": 0.22,
	"totalSharesOutStanding": 3146772,
	"sharesESCROW": null,
	"vwap": 4.59999999,
	"dividendPayDate": null,
	"weeks52high": 10.24,
	"weeks52low": 2.9,
	"alpha": -0.046216,
	"averageVolume10D": 1428,
	"averageVolume20D": 1243,
	"averageVolume30D": 1389,
	"averageVolume50D": 1631,
	"priceToBook": 1.04,
	"priceToCashFlow": -1.1,
	"returnOnEquity": -114.32,
	"returnOnAssets": -41.99,
	"day21MovingAvg": 4.777619,
	"day50MovingAvg": 4.8306,
	"day200MovingAvg": 4.4979,
	"dividend3Years": "",
	"dividend5Years": "",
	"datatype": "equity",
	"issueType": "CS",
	"close": 4.6,
	"qmdescription": "Biotechnology",
	"__typename": "Company"
}